Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 19, Issue 8, 2012, Pages 568-573

  Girardin, F ^a,b   Daali, Y ^a   Gex Fabry, M ^b   Rebsamen, M ^b   Roux Lombard, P ^b   Cerny, A ^c   Bihl, F ^b,d   Binek, J ^e   Moradpour, D ^f   Negro, F ^b   Desmeules, J ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Clinica Luganese Moncuco   (Switzerland)

^d OSPEDALE SAN GIOVANNI   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

CYP2D6; genotype phenotype; HCV Cohort Study; hepatitis C; liver antibodies

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; LIVER KIDNEY MICROSOMAL TYPE 1 ANTIBODY; MICROSOME ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; AUTOANTIBODIES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SWITZERLAND;

EID: 84863723376     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01578.x     Document Type: Article

References (21)

1. Drygiannakis D, Lionis C, Drygiannakis I, Pappas G, Kouroumalis E,. Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, Greece. BMC Gastroenterol 2001; 1: 4.
2. Miyakawa H, Kitazawa E, Kikuchi K, et al. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C. Autoimmunity 2000; 33 (1): 23-32.
3. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26 (3): 561-566.
4. Dalekos GN, Obermayer-Straub P, Bartels M, et al. Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J Hepatol 2003; 39 (5): 800-806.
5. Manns MP, Obermayer-Straub P,. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26 (4): 1054-1066.
6. Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7 (6): 1333-1339.
7. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA,. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci U S A 1988; 85 (21): 8256-8260.
8. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F,. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007; 36 (4): 731-737.
9. Becquemont L, Chazouilleres O, Serfaty L, et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 2002; 71 (6): 488-495.
10. Samer CF, Daali Y, Wagner M, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 2010; 160 (4): 907-918.
11. Schadel M, Wu D, Otton SV, Kalow W, Sellers EM,. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 1995; 15 (4): 263-269.
12. de Graan AJ, Teunissen SF, de Vos FY, et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 2011; 29 (24): 3240-3246.
13. Daali Y, Cherkaoui S, Doffey-Lazeyras F, Dayer P, Desmeules JA,. Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 861 (1): 56-63.
14. Rebsamen MC, Desmeules J, Daali Y, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 2009; 9 (1): 34-41.
15. Zhou SF,. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009; 48 (11): 689-723.
16. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF,. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev 2009; 41 (4): 573-643.
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
18. Li J, Zhao M, He P, Hidalgo M, Baker SD,. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13 (12): 3731-3737.
19. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17 (5): 589-595.
20. Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011; 39 (3): 510-521.
21. Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem 2006; 281 (11): 7614-7622.